earnings

Orthopedics companies’ nightmare quarter
Orthopedics companies’ nightmare quarter
EP Vantage
earnings
COVID-19
pandemic
Orthopedics
Medtronic
Thermofisher
Qiagen
ResMed
Zimmer Biomet
JNJ
Flag link:
PPD squeezes out a revenue growth despite COVID-19 disruption
PPD squeezes out a revenue growth despite COVID-19 disruption
Fierce Biotech
PPD
CROs
earnings
Flag link:
How Zoetis Beat Expectations Again in Q2
How Zoetis Beat Expectations Again in Q2
Motley Fool
Zoetis
animal health
earnings
Flag link:
Why Arena Pharmaceuticals' Q2 Results Don't Matter
Why Arena Pharmaceuticals' Q2 Results Don't Matter
Motley Fool
earnings
Arena Pharmaceuticals
Refinitiv
Flag link:
Moderna’s second-quarter revenue jumps fivefold on coronavirus vaccine development
Moderna’s second-quarter revenue jumps fivefold on coronavirus vaccine development
CNBC
Moderna Therapeutics
earnings
vaccines
COVID-19
Flag link:
Regeneron profit beats, expects early results from COVID-19 trials in September
Regeneron profit beats, expects early results from COVID-19 trials in September
Yahoo/Reuters
Regeneron
earnings
COVID-19
Flag link:
How Biomarin Beat Expectations in Q2
How Biomarin Beat Expectations in Q2
Motley Fool
Biomarin
earnings
Flag link:
What's Behind Jazz Pharmaceuticals' Q2 Revenue and Earnings Beats
What's Behind Jazz Pharmaceuticals' Q2 Revenue and Earnings Beats
Motley Fool
Jazz Pharmaceuticals
earnings
Flag link:
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Fierce Pharma
Bayer
earnings
China
pandemic
COVID-19
Eylea
Flag link:
Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own
Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own
Fierce Pharma
Amarin
Vascepa
earnings
Europe
Flag link:
What's Behind Pacific Biosciences of California's Ugly Q2 Results?
What's Behind Pacific Biosciences of California's Ugly Q2 Results?
Motley Fool
Pacific Biosciences
earnings
Flag link:
How Neurocrine Biosciences Crushed It in Q2
How Neurocrine Biosciences Crushed It in Q2
Motley Fool
Neurocrine Biosciences
earnings
Flag link:
AbbVie shares rises on strong Q2, though cosmetic Botox sales tumbled 43%
AbbVie shares rises on strong Q2, though cosmetic Botox sales tumbled 43%
Marketwatch
AbbVie
earnings
Flag link:
Stryker Beats Consensus but Still Feels COVID-19 Sting
Stryker Beats Consensus but Still Feels COVID-19 Sting
Medical Devices and Diagnostics Industry
devices
Stryker
earnings
Flag link:
Stryker dips despite Street-beating Q2
Stryker dips despite Street-beating Q2
Mass Device
Stryker
earnings
devices
Flag link:
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Motley Fool
EXACT Sciences
earnings
Flag link:
How Vertex Pharmaceuticals Wowed With Its Q2 Results
How Vertex Pharmaceuticals Wowed With Its Q2 Results
Motley Fool
Vertex Pharmaceuticals
earnings
Flag link:
Gilead Sciences' Revenue and Earnings Slip in Second Quarter
Gilead Sciences' Revenue and Earnings Slip in Second Quarter
Motley Fool
Gilead Sciences
earnings
Flag link:
Eli Lilly's stock rallies after a profit beat and raised outlook, although revenue fell short
Eli Lilly's stock rallies after a profit beat and raised outlook, although revenue fell short
Marketwatch
earnings
Eli Lilly
Flag link:
AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio
AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio
Yahoo/Benzinga
earnings
AstraZeneca
Flag link:

Pages